<DOC>
	<DOCNO>NCT02693197</DOCNO>
	<brief_summary>The primary objective determine single-dose pharmacokinetics ( PK ) T-817 T-817M5 ( metabolite T-817 ) subject mild , moderate severe hepatic impairment compare match healthy control subject . The secondary objective determine safety tolerability single-dose T -817MA ( Maleate salt T-817 ) subject mild , moderate severe hepatic impairment .</brief_summary>
	<brief_title>PK Study T-817 Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>For subject mild , moderate severe hepatic impairment 1 . Adult male female , 18 75 year age 2 . Must weigh least 50 kg body mass index ( BMI ) ≥ 18.5 ≤ 40.0 kg/m2 3 . Have mild , moderate severe define ChildPugh classification hepatic impairment For Matched Healthy Control Subjects Healthy adult male female subject match 1:1 specific subject mild , moderate , severe hepatic impairment cohort base upon age , weight , gender , smoke status 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . 2 . History presence clinically significant medical psychiatric condition disease opinion PI . 3 . History presence hypersensitivity idiosyncratic reaction study drug , related compound , inactive ingredient . 4 . Female subject pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatic Impairment</keyword>
</DOC>